Kyverna Therapeutics Q2 2024 Earnings Report

Kyverna Therapeutics EPS Results

• Actual EPS: -$0.67
• Consensus EPS: -$0.70
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: N/A

Kyverna Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $3.75 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Kyverna Therapeutics Announcement Details

• Quarter: Q2 2024
• Date: 8/12/2024
• Time: After Market Closes

Kyverna Therapeutics (NASDAQ:KYTX), a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.